Researchers use AI to identify drugs that could be repurposed for Alzheimer’s Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing Researchers from Harvard Medical School and Massachussetts General Hospital have revealed which drugs could be potentially repurposed as possible treatments for Alzheimer’s disease using artificial intelligence (AI). The research team developed an AI-based method that enabled them to screen US Food and Drug Administration (FDA) approved medications for their potential as repurposed Alzheimer’s treatments. The study, published in Nature Communications, used a framework called DRIAD (Drug Repurposing in Alzheimer’s Disease) which uses machine learning to measure what happens to human brain neural cells when treated with a drug.